IRA’s Orphan Drug Exemption Could Lead to More Off-Label Prescribing

 
• By Sarah Karlin-Smith
  
Zebras
Rare disease advocates believe IRA will jeopardize filing of supplemental marketing applications for orphan drugs. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Rare Diseases

More from Pink Sheet